Baxter appeases EU regulators in $4B Gambro buyout

Thu, 08/22/2013 - 12:51pm
Mass Device

The EU accepts Baxter's concessions over anti-monopoly concerns, allowing the $4B buyout of Swedish dialysis giant Gambro AB to go forward.

Baxter appeases EU regulators, closes $4B Gambro buyout

After months of negotiations with EuroZone regulators, Baxter's (NYSE:BAX) nearly $4 billion buyout of Swedish dialysis maker Gambro AB can go forward now that Baxter agreed to sell off its renal replacement therapy division to ease anti-trust concerns.

The buyout would give Baxter a strong grasp on the dialysis devices market. Soon after the deal was announced, European regulators threw up a red flag over monopoly concerns, forcing Baxter to propose concessions.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.